CULLINAN THERAPEUTICS, INC.: 10-Q filed 2024-11-07
What CULLINAN THERAPEUTICS, INC. reported in its quarterly report filed 2024-11-07 (fiscal Q3 2024): 36 published measures, 105 facts as tagged in accession 0000950170-24-122795.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2024-11-07
- Fiscal period
- fiscal Q3 2024
- Accession
- 0000950170-24-122795 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CULLINAN THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 653,254,000 | USD | |
| At 2023-12-31 | 484,182,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 25,392,000 | USD | |
| At 2023-12-31 | 30,287,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 627,862,000 | USD | |
| At 2023-12-31 | 453,703,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 102,085,000 | USD | |
| At 2023-12-31 | 98,434,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | -40,560,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -119,736,000 | USD | 274 |
| 2023-07-01 to 2023-09-30 | -39,183,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -129,359,000 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-09-30 | -108,677,000 | USD | 274 |
| 2023-01-01 to 2023-09-30 | -116,144,000 | USD | 273 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-09-30 | 0 | USD | 274 |
| 2023-01-01 to 2023-09-30 | 208,000 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-09-30 | 264,606,000 | USD | 274 |
| 2023-01-01 to 2023-09-30 | 40,503,000 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-09-30 | -152,278,000 | USD | 274 |
| 2023-01-01 to 2023-09-30 | -15,664,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | -320,593,000 | USD | |
| At 2023-12-31 | -200,857,000 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | 58,337,000 | shares | 92 |
| 2024-01-01 to 2024-09-30 | 52,157,000 | shares | 274 |
| 2023-07-01 to 2023-09-30 | 42,734,000 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 41,130,000 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | 58,337,000 | shares | 92 |
| 2024-01-01 to 2024-09-30 | 52,157,000 | shares | 274 |
| 2023-07-01 to 2023-09-30 | 42,734,000 | shares | 92 |
| 2023-01-01 to 2023-09-30 | 41,130,000 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | -0.69 | USD/shares | 92 |
| 2024-01-01 to 2024-09-30 | -2.3 | USD/shares | 274 |
| 2023-07-01 to 2023-09-30 | -0.91 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -3.15 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | -0.69 | USD/shares | 92 |
| 2024-01-01 to 2024-09-30 | -2.3 | USD/shares | 274 |
| 2023-07-01 to 2023-09-30 | -0.91 | USD/shares | 92 |
| 2023-01-01 to 2023-09-30 | -3.15 | USD/shares | 273 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 760,000 | USD | |
| At 2023-12-31 | 989,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-09-30 | 28,190,000 | USD | 274 |
| 2023-01-01 to 2023-09-30 | 22,919,000 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | -48,855,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -141,871,000 | USD | 274 |
| 2023-07-01 to 2023-09-30 | -45,243,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -145,604,000 | USD | 273 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 592,039,000 | USD | |
| At 2023-12-31 | 480,191,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 24,204,000 | USD | |
| At 2023-12-31 | 28,137,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 2,115,000 | USD | |
| At 2023-12-31 | 2,493,000 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | 48,855,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 141,871,000 | USD | 274 |
| 2023-07-01 to 2023-09-30 | 44,803,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 145,164,000 | USD | 273 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | 35,506,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 102,411,000 | USD | 274 |
| 2023-07-01 to 2023-09-30 | 33,821,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 113,308,000 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 58,141,130 | shares | |
| At 2023-12-31 | 42,900,083 | shares |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 970,000 | USD | |
| At 2023-12-31 | -129,000 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 627,862,000 | USD | |
| At 2024-06-30 | 656,221,000 | USD | |
| At 2024-03-31 | 425,665,000 | USD | |
| At 2023-12-31 | 453,895,000 | USD | |
| At 2023-09-30 | 468,817,000 | USD | |
| At 2023-06-30 | 499,574,000 | USD | |
| At 2023-03-31 | 485,649,000 | USD | |
| At 2022-12-31 | 535,029,000 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 2,019,000 | USD | |
| At 2023-12-31 | 2,543,000 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 2,446,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 460,000 | USD | |
| At 2023-12-31 | 459,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-09-30 | 20,831,000 | USD | |
| At 2023-12-31 | 24,204,000 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | -40,560,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -119,928,000 | USD | 274 |
| 2024-04-01 to 2024-06-30 | -42,028,000 | USD | 91 |
| 2024-01-01 to 2024-03-31 | -37,340,000 | USD | 91 |
| 2023-07-01 to 2023-09-30 | -39,183,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -129,538,000 | USD | 273 |
| 2023-04-01 to 2023-06-30 | -32,214,000 | USD | 91 |
| 2023-01-01 to 2023-03-31 | -58,141,000 | USD | 90 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | -39,114,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -118,637,000 | USD | 274 |
| 2023-07-01 to 2023-09-30 | -38,609,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | -127,809,000 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | 13,349,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | 39,460,000 | USD | 274 |
| 2023-07-01 to 2023-09-30 | 10,982,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 31,856,000 | USD | 273 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-09-30 | 229,000 | USD | 274 |
| 2023-01-01 to 2023-09-30 | 233,000 | USD | 273 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-07-01 to 2024-09-30 | -89,000 | USD | 92 |
| 2024-01-01 to 2024-09-30 | -205,000 | USD | 274 |
| 2023-07-01 to 2023-09-30 | 180,000 | USD | 92 |
| 2023-01-01 to 2023-09-30 | 356,000 | USD | 273 |
Income taxes paid, net
Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-09-30 | -2,274,000 | USD | 274 |
| 2023-01-01 to 2023-09-30 | 4,708,000 | USD | 273 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-09-30 | -378,000 | USD | 274 |
| 2023-01-01 to 2023-09-30 | -1,709,000 | USD | 273 |
Inspect the source
- Entity
- CULLINAN THERAPEUTICS, INC. / CIK 0001789972
- Captured
- 2026-09-21T17:27:31.629Z
- SEC response SHA-256
b27fca20bc22c828a65d8527782bea255b37a5346a489a029a3dfe906e83bfd0
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001789972.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))